

**Amended Claims:**

1. (amended) A pharmaceutical composition comprising a solid dispersion of an HIV protease inhibitor or a combination of HIV protease inhibitors **[and] in** a water soluble carrier **wherein the HIV protease inhibitor or the combination of HIV protease inhibitors is in amorphous form in the dispersion.**

5. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is selected from the group consisting of:

(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)[-amino]-1,6-diphenyl-3-hydroxyhexane (ritonavir);

(2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378);

N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl -4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginy]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S\*] ] -N'-[3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;

VX-478; DMP-323; DMP-450; AG1343 (nelfinavir);

BMS 186,318; SC-55389a; BILA 1096 BS; U-140690, **[or]** and combinations thereof.

6. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)**[-amino]**-1,6-diphenyl-3-hydroxyhexane (ritonavir).

8. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)**[-amino]**-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

20. (amended) The method of Claim 19 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)**[-amino]**-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

21. The method of Claim 19 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)**[-amino]**-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

**New Claims:**

22. (new claim) A pharmaceutical composition comprising a dispersion of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in a water soluble carrier wherein the ritonavir is in amorphous form in the dispersion.

23. (new claim) The composition of Claim 22 wherein said water soluble carrier is polyethylene glycol (PEG).

24. (new claim) A pharmaceutical composition comprising a dispersion of (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378) in a water soluble carrier wherein the ABT-378 is in amorphous form in the dispersion.

25. (new claim) The composition of Claim 24 wherein said water soluble carrier is polyethylene glycol (PEG).

26. (new claim) A pharmaceutical composition comprising a dispersion of a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378) in a water soluble carrier wherein the ritonavir and ABT-378 are in amorphous form in the dispersion.

27. (new claim) The composition of Claim 26 wherein said water soluble carrier is polyethylene glycol (PEG).

28. (new claim) A pharmaceutical composition comprising a dispersion of nelfinavir in a water soluble carrier wherein the nelfinavir is in amorphous form in the dispersion.

29. (new claim) The composition of Claim 28 wherein said water soluble carrier is polyethylene glycol (PEG).